Drug Trial Radar · NCT07099638
Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
496
Planned (sponsor's estimate)
Start
Jul 21, 2026
Primary completion
Jun 1, 2029
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- University of OklahomaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); Brown University; Thomas Jefferson University; Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
No published studies to date have evaluated the combined impact of varenicline and oral nicotine replacement therapy (NRT) on smoking cessation in a randomized trial. Oral NRT, such as nicotine lozenges, can provide acute relief from cravings/withdrawal, and offers individuals the flexibility to deliver nicotine quickly, in contrast with the continuous, passive, and slow-acting delivery of the nicotine patch. Nevertheless, in clinical trials of other combination pharmacotherapies, participants' adherence to of oral NRT has been suboptimal, making it difficult to determine whether there is an added benefit. Given the near-ubiquity of smartphone ownership (85% of U.S. adults), it is plausible that smartphone-based medication adherence interventions could have a positive influence on pharmacotherapy adherence and smoking cessation. This investigative team has demonstrated the feasibility and potential efficacy of using combination varenicline plus oral NRT treatment to promote smoking cessation in a pilot factorial randomized trial. Likewise, pilot findings showed that medication adherence and smoking cessation rates were higher among those who received smartphone-based medication reminders than those who did not. The proposed study will enroll 496 adults who smoke cigarettes daily. The study will employ a 2x2 factorial design in which participants will be randomized to one of four combinations of two treatment factors: 1) pharmacological treatment (varenicline + nicotine lozenges vs. varenicline alone) and 2) smartphone medication adherence intervention (smartphone-based smoking cessation app with vs. without adherence components). The primary study outcomes will be biochemically-confirmed 7-day point prevalence abstinence at 26 weeks after a scheduled quit date, and medication adherence over the 13-week treatment period. Smartphone-based daily diaries will be employed to assess daily smoking and medication adherence. Notably, the proposed study will employ entirely remote assessment and treatment delivery strategies. Exploratory analyses will evaluate the potential interaction between medication type and the smartphone adherence intervention, and compare the influences of pharmacological treatment type and the medication adherence intervention on weekly physical symptoms (e.g., withdrawal, medication side effects). The overarching goal of the proposed research is to improve smoking cessation treatment and decrease cancer risk.
Conditions
- Smoking Cessation
Interventions
Varenicline (VAR)Drug
13 weeks of varenicline
Nicotine lozenge (NRT)Drug
12 weeks of nicotine lozenges
Smartphone intervention with adherence components (COMBO-A)Behavioral
Smartphone-based smoking cessation intervention with adherence components
Smartphone intervention without adherence components (COMBO-B)Behavioral
Smartphone-based smoking cessation intervention without adherence components
Telephone CounselingBehavioral
Up to 6 telephone counseling sessions with a tobacco treatment specialist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Smoking Abstinence (26 weeks post-quit)Time frame: 26 weeks after the scheduled quit day
- Medication Adherence (weekly)Time frame: Weekly starting on the quit day (for varenicline) or 1-week post-quit (for lozenges) through 12 weeks post-quit.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TSET Health Promotion Research Center
Oklahoma City, Oklahoma · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.